May 28, 2020
DURECT to Present at the Jefferies 2020 Virtual Health Care Conference
Mar 03, 2020
DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs
Jul 25, 2019
DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1
May 16, 2019
DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
Mar 04, 2019
DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call
Feb 21, 2019
DURECT Corporation to Participate in the Berenberg NASH Day
Jan 07, 2019
DURECT Corporation Provides Corporate Update
Jan 03, 2019
DURECT Corporation Announces Investor Call to Provide Corporate Update
Dec 19, 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Nov 01, 2018
DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call
Oct 25, 2018
DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings
Oct 01, 2018
DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer
Sep 18, 2018
DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan
Aug 30, 2018
DURECT Announces Receipt of $5 Million Milestone Payment from Indivior
Dec 13, 2017
DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot
Nov 01, 2017
DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update
Oct 02, 2017
DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement
Sep 20, 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
Aug 08, 2017
DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update